Nagasaki T, Ohkubo T, Sugawar K, Yasui N, Ohtani K, Kaneko S
Department of Pharmacy, Hirosaki University Hospital, Japan.
J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):293-8. doi: 10.1016/s0378-4347(98)00212-6.
A high-performance liquid chromatographic method using an electrochemical detector (HPLC-ED) was developed for the determination of nemonapride and its active metabolite, desmethylnemonapride in human plasma. Nemonapride, desmethylnemonapride and moperone chloride, which was used as the internal standard (I.S.) in plasma, were extracted by a rapid and simple procedure based on C18 bonded-phase extraction, and were separated by C8 reversed-phase HPLC column. Nemonapride and desmethylnemonapride were detected by high conversion efficiency amperometric detection at +0.84 V. Determination of both nemonapride and desmethylnemonapride were possible in the concentration range at 0.25-5.0 ng/ml, and the limit of detection for each was 0.1 ng/ml. The recoveries of nemonapride and desmethylnemonapride added to plasma were 97.0-98.2% and 96.7-98.8%, respectively, with coefficients of variation of less than 7.2% and 10.3%, respectively. This method is applicable to drug level monitoring in the plasma of schizophrenia patients treated with nemonapride and to the study of pharmacokinetics.
建立了一种使用电化学检测器的高效液相色谱法(HPLC-ED),用于测定人血浆中的奈莫必利及其活性代谢物去甲基奈莫必利。血浆中的奈莫必利、去甲基奈莫必利和用作内标(I.S.)的氯莫哌隆,通过基于C18键合相萃取的快速简单程序进行萃取,并通过C8反相HPLC柱进行分离。奈莫必利和去甲基奈莫必利通过在+0.84 V下的高转换效率安培检测进行检测。在0.25-5.0 ng/ml的浓度范围内可以同时测定奈莫必利和去甲基奈莫必利,各自的检测限为0.1 ng/ml。添加到血浆中的奈莫必利和去甲基奈莫必利的回收率分别为97.0-98.2%和96.7-98.8%,变异系数分别小于7.2%和10.3%。该方法适用于接受奈莫必利治疗的精神分裂症患者血浆中的药物水平监测以及药代动力学研究。